Core Viewpoint - MediPharm Labs Corp. announces the resignation of CEO David Pidduck, effective January 23, 2026, with CFO Greg Hunter appointed as Interim CEO while the Board evaluates long-term leadership plans [1][2]. Group 1: Leadership Transition - David Pidduck has been instrumental in stabilizing and repositioning the company, successfully executing restructuring initiatives and improving profitability [2]. - Greg Hunter, appointed as Interim CEO, has a strong background in financial management and has implemented cost-reduction initiatives, enhancing financial and operational controls since becoming CFO in February 2021 [3][4]. - The Board expresses confidence in Hunter's ability to drive execution and operational discipline during this transition period [5]. Group 2: Company Background - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and advanced derivative products in a GMP-certified facility [6]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale, domestic GMP license for extracting multiple natural cannabinoids [7]. - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to Canadian medical patients and enhancing its international operations [8].

Core Viewpoint - MediPharm Labs Corp. reported strong year-over-year revenue growth for Q3 2025, driven by its international medical cannabis strategy, while also reducing costs and increasing cash reserves [2][3]. Financial Performance - Q3 2025 revenue reached $11.4 million, marking a 17% increase from $9.8 million in Q3 2024, attributed to growth in international business [4][8]. - International medical cannabis revenue was $6.4 million, representing 56% of total revenue, with an 83% year-over-year growth [5][8]. - Canadian adult-use and wellness revenue was $1.8 million, reflecting a 4% year-over-year increase and 9% sequential growth from Q2 2025 [5]. Cost Management - Operating expenses decreased to $4.4 million in Q3 2025, down 19% year-over-year and 35% sequentially [9][8]. - Gross profit for the quarter was $2.6 million, with a gross margin of 22%, indicating margin pressure from product mix [7][10]. Cash Position - The company ended Q3 2025 with a cash balance of $10.6 million, an increase of $0.2 million from Q2 2025, supported by disciplined cash management and asset sales [11][12]. Business Strategy - The company expanded its inhaler product line in the domestic market and launched metered dose inhalers in Australia, with plans for future launches in other international markets [6][5]. - Management remains focused on driving revenue growth and streamlining expenses to enhance profitability [3][9].

Core Points - MediPharm Labs Corp. held its annual and special meeting where key resolutions were voted on by shareholders [1][2] - A total of 210,726,733 common shares were represented, accounting for 50.76% of the total issued shares [2] - The meeting resulted in the approval of several resolutions including the number of directors, appointment of auditors, election of directors, and unallocated awards under the equity incentive plan [3] Voting Results - The resolution to fix the number of directors at seven was approved with 75.46% voting in favor [5] - All management director nominees were elected with Chris Halyk receiving 144,007,422 votes and Emily Jameson receiving 144,289,930 votes [6] - MNP LLP was appointed as the auditor with 90.78% of votes in favor [7] - The resolution for unallocated awards under the equity incentive plan was narrowly approved with 50.14% voting for and 49.86% against [8] Board Changes - New directors Emily Jameson and John Medland were welcomed to the Board, while Michael Bumby did not stand for re-election [4] Company Overview - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and advanced derivative products [9] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [10] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [11]

Core Viewpoint - MediPharm Labs Corp. is urging shareholders to be cautious regarding the election of three Dissident Nominees associated with Apollo Technology Capital Corporation, citing concerns over their past involvement with Check-Cap Ltd. and its governance issues [1][2][18]. Summary of Recent Events at Check-Cap - Check-Cap has faced significant governance challenges, including poor transparency, high turnover, and questionable cash resource allocation, leading to a decline in shareholder value [3][6]. - A notable incident involved Check-Cap transferring millions of dollars to Apollo and its subsidiaries, which raises concerns about the motives of the Dissident Nominees [4][11]. - The Check-Cap Board approved a $6 million loan to Nobul and transferred $11 million to a segregated account for Nobul's growth initiatives, despite no formal business combination being completed [8][9]. Connections to the Dissident Nominees - Three of the six Dissident Nominees for MediPharm's Board have been directly involved in Check-Cap's governance issues, raising questions about their qualifications to lead another public company [11][14]. - The involvement of these individuals in Check-Cap's tumultuous history suggests a potential risk for MediPharm shareholders [12][18]. Shareholder Voting Assistance - MediPharm encourages shareholders to vote using the GREEN proxy in support of the Company's nominees, emphasizing the importance of disregarding communications from the Dissident Nominees [19][20]. Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis products and has a GMP license from Health Canada, positioning it as a leader in the cannabinoid sector [21][23]. - The Company expanded its reach through the acquisition of VIVO Cannabis Inc., enhancing its presence in the medical cannabis market [24].